Disease · HP_0002747
Respiratory insufficiency due to muscle weakness
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Respiratory insufficiency due to muscle weakness. Diseases, record HP_0002747. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002747
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Respiratory insufficiency due to muscle weakness
- Open Targets ID
- HP_0002747
- Other names
Decreased lung function due to weak breathing muscles, Decreased respiratory function due to muscle weakness, Respiratory distress due to muscle weakness, Respiratory failure due to muscle weakness, Respiratory muscle weakness
- Highest stage of its drugs
- Phase 3, for 2 of its 4 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs4
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ALGLUCOSIDASE ALFA | CHEMBL1201824 | Enzyme | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AVALGLUCOSIDASE ALFA | CHEMBL4594320 | Enzyme | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HMB | CHEMBL4525124 | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| ICOSAPENT | CHEMBL460026 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets0
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
None in this release.
Trials2
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02782741 | Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease | Phase 3 | 101 | 2021-04-08 | Glycogen Storage Disease Type II;Pompe's Disease | ALGLUCOSIDASE ALFA, AVALGLUCOSIDASE ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT01270516 | Effect of EPA and HMB on Strength in ICU Patients | Not applicable | 73 | 2021-04-12 | Muscle Weakness | ICOSAPENT | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002747
GET https://conductscience.org/api/diseases/v1/HP_0002747/drugs